Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski, Christopher P. Fox, Elisabeth Schorb, Claudia Celico, Monica Falautano, Alessandro Nonis, Paul La Rosée, Mascha Binder, Alberto Fabbri, Fiorella Ilariucci, Mauro Krampera, Alexander Röth, Claire Hemmaway, Peter Johnson, Kim Linton, Tobias Pukrop, Jettes Sønderskov Gørløv, Monica Balzarotti, Georg Heß, Ulrich Keller, Stephan Stilgenbauer, Jense Panse, Alessandra Tucci, Lorella Orsucci, Francesco Pisani, Manuela Zanni, Stefan W. Krause, Hans‐Joachim Schmoll, Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Lorenz Thurner, Giuseppina Cabras, Elsa Pennese, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Jürgen Finke, Antonella Ferranti, Kelly Cozens, Elvira Burger, Nicoletta Ielmini, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, IELSG32 study investigators